DMD treatment landscape, 2026 mid-year reference
Reference layout of the Duchenne muscular dystrophy treatment landscape as of mid-2026: approved mechanisms across exon-skipping, gene therapy, and corticosteroid-class agents, late-stage pipeline, and the live commercial questions across patient populations.
Reference layout of the Duchenne muscular dystrophy treatment landscape as of mid-2026. Includes approved mechanisms across exon-skipping antisense oligonucleotides, gene therapy, corticosteroid agents, and adjacent classes, late-stage pipeline, and the live commercial questions across patient populations. DMD is now a multi-mechanism therapeutic area with the commercial conversation having moved from whether treatment exists to which treatment for which patient at which stage.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.